CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Clinical trial NCT06548412 · RECRUITING
Trial details
- NCT number
- NCT06548412
- Sponsor
- M.D. Anderson Cancer Center
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-01-22
- Primary completion
- 2027-05-01
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.